Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Ozempic, Wegovy face US Medicare price negotiations
Novo Suffers Wegovy Trial Setback as US Plans to Cut Price
Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early dominance in the surging market for new weight-loss treatments.
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
High-dose Wegovy leads to substantial weight loss in trial
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP trial to evaluate the effect of increasing the maximum dose to 7.2 mg. The trial randomized 1,407 adults with obesity, but not diabetes, to receive either 7.2 mg or 2.4 mg of semaglutide or placebo.
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
13h
on MSN
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
12h
on MSN
These Stocks Are Moving the Most Today: Apple, Qorvo, Novo Nordisk, SLB, J.B. Hunt, Rivian, Cloudflare, and More
Stocks rallied sharply Friday and the S&P 500 was on pace for its best week since early November.These stocks were making ...
14h
on MSN
Novo’s Wegovy Trails Lilly’s Zepbound in Higher-Dose Study
Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Los Angeles wildfire updates
California fires: How to help
To go dark on Sunday
Cabinet approves Gaza deal
To skip Trump’s inauguration
Opposes Fani Willis' bid
Senate confirmation hearing
Polar vortex to freeze US
Sign partnership treaty
Denied bail in assault case
Texas abortion pill ruling
To fill Vance’s Senate seat
FTC sues PepsiCo
Pence advocates for Taiwan
Navalny lawyers sentenced
CA battery storage plant fire
Liable for defaming veteran
Former NBA champion dies
Acting legend Plowright dies
New Pompeii excavation
NHTSA probing GM vehicles
Attempted attack sentencing
Bitcoin soars past $100K
US drops corruption case
Khan gets 14-year jail term
Commutes more sentences
Apple halts AI news alerts
To negotiate drug prices
Calls for stronger sanctions
DOJ sues Houston County
Related topics
Donald Trump
United States
Greenland
Zepbound
Denmark
Feedback